The pharmaceutical industry has never been more exciting. At the dawn of this new decade, we are seeing incredible scientific breakthroughs in the industry. Gene therapy is becoming a reality, clinical diagnostics combined with treatments are paving the path for personalized medicine, and often under-represented diseases, like sickle cell disease and spinal muscular atrophy, are seeing not just one new treatment, but multiple life-changing solutions entering the market in 2019 and continuing in 2020. With all this change and excitement, there has been a whole lot of change within brand marketing organizations.

Researchers discovered the remains of a dinosaur from what is now modern Alberta, Canada that contains evidence of having suffered a condition similar to a rare cancer of the bone marrow.

In August 1963, the Rev. Martin Luther King delivered his famous “I Have a Dream” speech that called for equality among all people, regardless of their ethnicity, as well as a vision for a better America for all. While the noble dreams that King outlined on that hot day in Washington, D.C. so many years ago have unfortunately not yet been fully realized, there are other kinds of dreams that may be closer to being achieved, particularly in the area of new medications for serious diseases.

PhoreMost entered into a multi-project drug discovery collaboration with Boehringer Ingelheim to develop innovative therapies for diseases with unsatisfactory treatments.

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.

Outcome Health has partnered with Unity Consortium to create video spots launching a new campaign designed to encourage young adults and teens to get up-to-date with recommended vaccinations and to teach them how to spot vaccine-related misinformation on the internet.

A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.

The advent of increasingly more mainstream and affordable genetic testing enables powerful genetic research – but that power is directly associated with the strength and diversity of the database of genetic information available.

Lyra Therapeutics Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced a $29.5 million Series B equity financing.

Americans may have a false sense of security about the privacy and safety of their personal medical information.